

ASML

Price EUR89.49

Crossed the line of an unattractive risk/reward**Fair Value EUR81 vs. EUR85 (-9%)****SELL vs. BUY**

Bloomberg	ASML.NA
Reuters	ASML.AS
12-month High / Low (EUR)	103.8 / 71.8
Market Cap (EURm)	38,779
Ev (BG Estimates) (EURm)	36,998
Avg. 6m daily volume (000)	1,309
3y EPS CAGR	21.8%

	1 M	3 M	6 M	31/12/15
Absolute perf.	3.4%	11.8%	15.9%	8.4%
Semiconductors	2.9%	2.8%	10.9%	-0.4%
DJ Stoxx 600	-2.1%	-6.2%	-3.8%	-8.6%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	6,287	6,485	7,419	8,742
% change		3.1%	14.4%	17.8%
EBITDA	1,864	1,920	2,345	3,031
EBIT	1,565	1,615	2,025	2,666
% change		3.2%	25.4%	31.6%
Net income	1,387	1,390	1,765	2,353
% change		0.2%	27.0%	33.3%

	2015	2016e	2017e	2018e
Operating margin	24.9	24.9	27.3	30.5
Net margin	22.1	21.4	23.8	26.9
ROE	16.5	16.8	19.7	23.5
ROCE	22.9	21.6	27.2	28.0
Gearing	-27.2	-21.5	-26.6	-15.4

(EUR)	2015	2016e	2017e	2018e
EPS	3.21	3.31	4.27	5.80
% change	-	3.0%	29.1%	35.8%
P/E	27.9x	27.1x	21.0x	15.4x
FCF yield (%)	3.8%	2.7%	4.6%	1.2%
Dividends (EUR)	0.70	1.05	1.21	1.39
Div yield (%)	0.8%	1.2%	1.3%	1.6%
EV/Sales	5.8x	5.7x	4.9x	4.3x
EV/EBITDA	19.6x	19.3x	15.5x	12.3x
EV/EBIT	23.3x	22.9x	18.0x	14.0x

In January, we upgraded ASML to Buy vs. Neutral to take advantage of improving NT momentum thanks to orders from 10nm capacity build starting from Q2 2016. After a ~17% stock price increase, we now adopt a Sell recommendation as 1/ we believe this NT momentum is fully priced in, 2/ we start to worry about high market expectations regarding DUV and 3/ we start to have doubts about the introduction of EUV technology by 2017. Indeed, with a slowdown in new node introduction and the adoption of 10nm tools starting in Q2, risks are higher for a delay in the 7nm introduction (which is seen as the trigger for EUV adoption). As a result, we believe ASML's risk/reward profile has moved into negative territory and recommend that investors seek a better opportunity (ARM/DLG/IFX). We downgrade our recommendation to Sell vs. Buy and cut our FV to EUR81 vs. EUR85.

ANALYSIS

- Improving momentum in DUV in the NT is already priced while the LT picture looks less attractive.** From its low point of EUR72 per share in February, the stock then rallied 25%, on the back of the prospect of better momentum in the core DUV business thanks to the introduction of 10nm at the largest Logic IDM and foundries (Intel, TSMC and Samsung) starting from Q2 2016. We expected this move (described in our [initiation report](#) published in September 2015) which explains why we adopted a Buy recommendation in January 2016. After this attractive performance, we now believe that all positive impacts of 10nm introduction are priced in leading us to look back at LT catalysts. Regarding the overall semiconductor market, we believe that the softening smartphone market and flat PC segment could weigh on leading edge chip demand and then on investments into leading edge capacities (recent trends and market expectations: capacities for new nodes are 10% lower than previous nodes). As a result, this could put pressure on 10nm front-end production capacity and lead the market to lower its expectations regarding demand for DUV lithography tools at foundries and Logic customers for FY16 and FY17 (BG ests. FY16/FY17 revenue of EUR6.49bn/EUR7.42bn vs. cons. EUR6.59bn/EUR7.45bn). Finally, in Memory, we believe that a potential uptick in investments by NAND manufacturers should not be considered as a strong catalyst for ASML since the current trend is multi-layer NAND which is not a litho-intensive production. As a result, we struggle to find unpriced catalysts in the current core business.
- EUV performance continues to improve but the EUV introduction point might be delayed.** Lately, ASML announced it had achieved a 1,368 wafer per day output (in-house) with its new machine, the NXE3350B. As a reminder, the group announced in December 2015 an output of 1,300 wafers per day. Today, the group is particularly confident in achieving 1,500 wafers per day by the end of 2016, which seems to be a fair assumption in our view given the recent improvements. In addition, the group recently announced that availability had reached 80% in some instances, i.e. the 2016 target is already achieved while availability was the main concern in 2015. Overall, EUV technology seems to be maturing and it should achieve a production level by 2017 as expected before. However, we start to worry about 1/ the timing of the 7nm ramp (expected to start from H2-17) given that orders for 10nm are expected to ramp by Q2-16 (i.e. about 1.5 years later) and 2/ the interest and readiness to start 7nm production with EUV tools given that the output would be significantly reduced with EUV while 10nm DUV tools could be reused for 7nm. Indeed, there is a risk that 10nm overall capacity remains limited after 7nm introduction given the reducing number of customer able to afford leading edge production while the industry would then focus on 7nm, as a result there is a higher risk that foundries reuse 10nm tools to ramp 7nm production while keeping a tight control on capex and moving slowly production (and capex) to EUV. This scenario would add pressure to both EUV and DUV tools demand in 2017 and 2018.
- An unattractive risk/reward.** The standalone company performance remains exceptional so far but we start to have some doubts regarding demand. Market momentum in leading edge manufacturing is clearly weakening (smartphone slowing down and PC flat) and although semiconductor end-market momentum does not directly affect front-end investments in the short term, we believe it rules LT investment strategies at Logic and Memory players. As a result, we see the group moving closer to our bear case scenario (see our [initiation report, page 33](#)) implying a slowdown in Moore's law and a delay in EUV adoption implying a failure to deliver the EUR10bn revenue target by 2020. All things being equal, using our bear scenario, the DCF-based valuation would be EUR60 (-33% downside) while using our bull case scenario (implying the EUR10bn



revenue target one year earlier in 2019) points to a DCF-based valuation of EUR95 (+6% upside) and our main scenario points to a FV of EUR83 or a downside of -8%. In addition, looking deeper into consensus expectations, we observe that FY2016 and FY2017 consensus' EPS decreased by -31% and -26% respectively over a one-year period (from EUR4.58 to EUR3.30 and EUR5.80 to EUR4.27) while the share price moved down by only 6% which adds further pressure to the group's current valuation. **As a result, our base case scenario appears to be fully priced in and it seems to us that the current risk/reward is negative on the stock, as a result we adopt a Sell recommendation and favour other stocks in the semiconductor industry such as ARM Holdings (Buy, FV 1,340p), Dialog (Buy, FV EUR39) and Infineon (Buy, FV EUR15) offering a better opportunity in our view.**

VALUATION

- **We have updated our model for FX and WACC assumptions.** We now use a EUR/USD exchange rate of 1.13 (vs. 1.09) and apply changes in our opex expectations (now stable vs. Q4 over FY16). The combination of these two adjustments has resulted in a 4% cut in EPS on average (FY16e/FY17e/FY18e). In addition, we now use new Bryan Garnier's risk free rate and equity risk premium assumptions of 1.6% and 7.0% respectively, leading to a WACC of 9.3% (vs. 9.0% used previously, we keep our 1.1 beta).
- **Our new FV is EUR81 vs. EUR85.** This new Fair Value of EUR81 stems from an equi-weighted average between a DCF valuation (FV of EUR84) and peer comparison taking account of ASML's historical premium to peers (FV of EUR78).
- **Based on our estimates, the share is trading on 2016e EV/EBIT of 22.9x and 2016e P/E of 27.0x.** Over 2016/18e our estimates show average annual EPS growth of 22%, pointing to 2016e PEG of 1.2x.

NEXT CATALYSTS

- 29th April 2016, General Meeting of shareholders.
- 20th April 2016, Q1 2016 results (before market opening).

Our new estimates

[EURm]	1Q16e	2Q16e	3Q16e	4Q16e	FY16e	FY17e	FY18e
Total Group	1282	1588	1731	1884	6485	7419	8742
Q/Q growth	-10.6%	23.9%	9.0%	8.8%	3.1%	14.4%	17.8%
Y/Y growth	-22.3%	-4.0%	11.7%	31.3%	3.1%	14.4%	17.8%
Cost of goods sold	-744	-858	-926	-1000	-3528	-3999	-4616
Gross margin	42.0%	46.0%	46.5%	46.9%	45.6%	46.1%	47.2%
R&D	-274	-272	-265	-259	-1070	-1098	-1162
SG&A	-87	-84	-88	-91	-350	-371	-376
Other operating income	22	21	19	16	78	74	79
Adj. EBIT	200	394	471	549	1615	2025	2666
adj. operating margin	15.6%	24.8%	27.2%	29.2%	24.9%	27.3%	30.5%
Net financial result	-3	-3	-3	-8	-17	-19	-23
Income tax	-26	-51	-61	-70	-208	-241	-291
tax rate	-13.0%	-13.0%	-13.0%	-13.0%	-13.0%	-12.0%	-11.0%
Adj. Net income	172	340	407	471	1390	1765	2353
Diluted adjusted EPS	0.41	0.81	0.97	1.12	3.31	4.27	5.80

Source: Bryan, Garnier & Co. ests.

[Click here to download](#)



Analyst :
Dorian Terral
33(0) 1.56.68.75.92
dterral@bryangarnier.com

Sector Team :
Richard-Maxime Beaudoux
Thomas Coudry
Gregory Ramirez

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 63.2%

NEUTRAL ratings 30.1%

SELL ratings 6.6%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudentiel et de		FINMA	
(FCA)	resolution (ACPR)			

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..